WebNews

Please enter a web search for web results.

NewsWeb

@MMMnews
mmm-online. com-online. com

The Escalator: Spectrum Science, Pfizer, Live World and more

50+ min ago  (768+ words) See which leaders are on the move across the pharma, biotech and medical marketing industries. Live World, a 2026 MM+M Ones to Watch honoree, named Rob Thomas as VP, creative director. Symeres and Axxam appointed Russell Thomas as chief scientific…...

Symbols: lupin.ns
Bio Spectrum Asia
biospectrumasia. com > news > 36 > 27995 > godavari-biorefineries-secures-japanese-patent-for-advanced-stem-cell-targeted-anti-cancer-molecule. html

Godavari Biorefineries secures Japanese patent for advanced stem-cell targeted anti-cancer molecule

46+ min ago  (1641+ words) July 9, 2026 | Thursday | News Godavari Biorefineries has been granted a patent by the Japan Patent Office for its breakthrough invention, "5-Hydroxy-1, 4-Naphthalenedione for use in the treatment of cancer." This patent covers a novel class of compounds that have demonstrated strong…...

Symbols: nasdaq:orka
Bio Xconomy
bioxconomy. com > partnering > sino-lands-second-mega-deal-with-az-2-1bn-licensing-agreement

Astra Zeneca licenses Sino's COPD drug for $2. 1bn

50+ min ago  (439+ words) Astra Zeneca pays Sino Biopharmaceutical $200 million upfront to challenge Merck & Co.'s Ohtuvayre in the treatment of chronic obstructive pulmonary disease. Astra Zeneca has agreed a licensing deal worth up to $2. 1 billion with Sino Biopharmaceutical for ex-China rights to its…...

Symbols: nyse:azn
Google News
aquafeed. com > newsroom > farming-news > portuguese-blue-bioeconomy-patents-struggle-to-reach-commercialization

Aquafeed. com | Portuguese blue bioeconomy patents struggle to reach commercialization

1+ hour, 12+ min ago  (767+ words) The first comprehensive mapping of Portugal's blue bioeconomy patents shows that although international patenting has accelerated over the past two decades, only 6% of technologies have progressed beyond laboratory validation. Over the past two decades, Portugal has generated 69 commercially oriented blue…...

Symbols: nyse:iff,nasdaq:biaf,nasdaq:anix
UKTN
uktech. news > medtech > life-sciences-pulled-in-over-3bn-since-since-sector-plan-launched-20260709

Life sciences pulled in over "3bn since since sector plan launched

2+ hour, 54+ min ago  (330+ words) The UK life sciences sector has attracted more than "3bn in new public-private investment in the past 12 months, marking the first year of a government plan for the industry. The Life Sciences Sector Plan was launched by the government in July…...

Symbols: btc-usd
Philenews
en. philenews. com > insider > medicover-genetics-showcases-impact-of-research-and-innovation-to-eu-commission-and-ministry-of-finance

Medicover Genetics showcases impact of research and innovation to EU Commission and Ministry of Finance

2+ hour, 4+ min ago  (513+ words) Philenews Medicover Genetics showcases impact of research and innovation to EU Commission and Ministry of Finance Medicover Genetics Cyprus welcomed on July 2nd 2026 a delegation from the Directorate-General for Regional and Urban Policy (DG REGIO) of the European Commission and the…...

Symbols: nasdaq:imux,nasdaq:rckt,symbol:alers
Whalesbook
whalesbook. com > corporate-news > English > healthcarebiotech > One Source-Specialty-Pharma-No-Material-Impact-from-DRL-Supply-Delay-Expands-Capacity > 6a4f2daeadc106bd16f8e292

One Source Specialty Pharma: No Material Impact from DRL Supply Delay; Expands Capacity

2+ hour, 38+ min ago  (409+ words) One Source Specialty Pharma reassured investors that a supply delay from partner Dr. Reddy's Laboratories has no material impact. The company highlighted diversified demand and confirmed new manufacturing capacity coming online this quarter. One Source Specialty Pharma has stated that…...

Symbols: btc-usd
Streamline
streamlinefeed. co. ke > news > astrazeneca-loses-kes-3-3-trillion-in-value-after-major-heart-drug-trial-fails

Astra Zeneca Loses KES 3. 3 Trillion in Value After Major Heart Drug Trial Fails

2+ hour, 15+ min ago  (272+ words) A Phase III trial failure for the ATTR-CM drug Wainua has wiped "20 billion from Astra Zeneca's market capitalization, sending shockwaves through global markets. The failure stems from the CARDIO-TTRansform study, the largest clinical trial ever conducted for ATTR-CM, encompassing 1, 432 patients…...

Symbols: lse:azn,nasdaq:azn
Be Beez International
bebeez. eu > 07/09/2026 > handspring-secures-a-19-million-us-dollars-round-from-angelini-ventures-and-other-investors

Handspring secures a 19 million US Dollars round from Angelini Ventures and other investors

3+ hour, 13+ min ago  (339+ words) Handspring Health announced a $19 million Series B. Handspring, an US virtual platform offering mental health support services for children, adolescents and young adults, secured a series B round of19 million US Dollarsthat Angelini Ventures, the corporate venture capital of the eponymous Italian…...

Symbols: btc-usd
Techsauce
techsauce. co > en > exec-insight > in-conversation-with-eric-tse

In Conversation with Eric Tse, Heir to One of China's Leading Pharmaceutical Groups, on Lessons from SBP Group's 20-Year Path to Global Success

2+ hour, 21+ min ago  (722+ words) July 9, 2026 | By Techsauce Team Eric Tse defines the company's identity as pioneer innovation, or being an innovation pioneer rather than a follower. But that was only the beginning. The next goal Eric is pushing the organization toward is to move…...

Symbols: btc-usd